AGCT GmbH

Liquid biopsy cancer testing Non-invasive liquid biopsy tests are aimed at fundamentally changing cancer diagnostics and treatment. Existing technologies have performance limitations and narrow the potentials of liquid biopsy. What we do AGCT develops a groundbreaking PCR-based assay technology that will introduce an unmatched limit of detection for liquid biopsy cancer testing. At the same time our technology can be applied on standard laboratory equipment. AGCT’s disruptive technology AGCT’s cyberPCR technology creates a new dimension of sensitivity and specificity in cancer detection. The proprietary technology already discriminates at the amplification step. Only mutant target sequences are amplified, permitting an unprecedented signal-noise ratio and a revolutionary level of rare mutant molecule detection for liquid biopsy.